MetaVia (MTVA) Amortization of Deferred Charges (2017 - 2024)

MetaVia's (MTVA) quarterly Amortization of Deferred Charges came in at $3000.0 in Q3 2024, up 200.0% on a QoQ basis from $1000.0 in Q1 2024.

MetaVia (MTVA) Amortization of Deferred Charges (2017 - 2024) Analysis & Trends

MetaVia (MTVA) has 5 years of Amortization of Deferred Charges data on file, last reported at $3000.0 in Q3 2024.

Quarterly Amortization of Deferred Charges changed N/A year-over-year to $3000.0 in Q3 2024, while the trailing twelve-month figure through Dec 2024 was $4000.0 (down 99.51% YoY) and the FY2024 annual result came in at $4000.0, up 300.0% from the prior year.
Amortization of Deferred Charges grew to $3000.0 in Q3 2024, from $1000.0 in the prior quarter.
In the past five years, Amortization of Deferred Charges ranged from a high of $3000.0 in Q3 2024 to a low of -$4000.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	MetaVia	8.72 Mn	-3.92 Mn	-

Download Data